TransEnterix, Inc., a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, announced that the first radical hysterectomy for cervical cancer utilizing its Senhance surgical robot was performed by gynecologic surgeon Dr. Salvatore Gueli Alletti, a member of Professor Giovanni Scambia’s team, at the Policlinico A. Gemelli Foundation in Rome, Italy.
“This is an exciting development in the minimally invasive surgical field. The Senhance system was successfully utilized to perform a radical hysterectomy with bilateral pelvic lymphadenectomy,” said Dr. Gueli Alletti. “This is an extensive oncological dissection, and the system’s precision, camera control, ergonomics and haptics were important benefits to help perform this operation safely and effectively. I strongly believe that the Senhance is a promising technology in complex gynecologic oncology.”
A radical hysterectomy is performed for early stage cervical cancer and involves the dissection and removal of all the uterus and parametria, ovaries, fallopian tubes and the upper portion of the vagina. The operation is a major cancer operation which includes an extensive pelvic lymph node dissection.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance surgical robotic system, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control.
The company is also developing the SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance surgical robotic system has been granted a CE Mark but is not currently available for sale in the United States. For more information: www.transenterix.com.
(Source: Business Wire)
